Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Mar 05, 2021 10:58am
159 Views
Post# 32727811

RE:RE:RE:RE:RE:Sedar

RE:RE:RE:RE:RE:SedarTo allow time for shareholders to digest the news and see the positive impact of the roll out before the annual vote I would expect the roll out is within the next 2 weeks and prior to the week of March 22.

And just so Jonny doesn't think I'm pumping because I'm reading into the Sedar document:  Tripp needs a martketing plan!!  He should be taking advantage of the upcoming Covid $1.9 billion bill and being likely 2 weeks or less from launch.  Create come momentum.



LithLover wrote: The voting is set for March 29!!  

No way he doesn't roll out Aristotle prior to the annual vote.  If Aristotle was delayed the annual meeting would not be in May with a vote end of March.

The roll out is going to be within the next 3 weeks!!


From Sedar:  document filed March 4, 2021

Date Fixed for the Meeting: May 17, 2021 
Record Date for Notice: March 29, 2021
Record Date for Voting: March 29, 2021






Nailbiter1 wrote: Finallllllly some good news.
LithLover wrote:

May 17 is also the day Q1 financials are due.  Q4 March 31.  Meeting is early this year.

in 2020 the annual meeting was Aug 17 and in 2019 and 2018 they were both in June.  
 

 

MoreUpThanDown wrote: Thanks Constructor. Notice of Annual and Special Meeting, date fixed for the meeting: 17 May 2021. Record Date for notice 29 March 2021... suppose this info will be added to a hopefully "all-in-one" NR soon, but not too soon as the market seems to need to settle down first. Add the meeting to the list of other info... I'm still long and hoping to be at the meeting in person this year since it's certainly to be an interesting one... All IMHO. Do your own DD.

 

 


 




<< Previous
Bullboard Posts
Next >>